Claim: a dual plasma miRNA gate may be a more defensible pre-TNF enrichment rule in RA than miR-134-5p alone
Claim
A dual plasma miRNA gate (miR-134-5p + miR-27a-3p) is a more defensible pre-TNF enrichment rule in rheumatoid arthritis than miR-134-5p alone, provided the assay is run in platelet-poor plasma with hemolysis control.
Evidence
- Prior RA work reported that baseline serum microRNAs can predict TNF-inhibitor response.
- A placebo-controlled early-RA trial found plasma miR-27a-3p associated with 12-month remission on adalimumab plus methotrexate.
- A 2026 report described plasma miR-134-5p as a candidate non-response biomarker for anti-TNF therapy.
- Hemolysis can alter plasma microRNA content, so pre-analytic QC is not optional.
ORVS check
- Scientific validity: moderate
- Novelty: moderate
- Clinical usefulness: potential enrichment gate, not a stand-alone classifier
- Safety: acceptable only as research framing
- Methodological coherence: contingent on platform harmonization and external validation
Inference
If the dual-marker model improves calibration more than discrimination, it may still be clinically useful as a decision-support gate.
Limitations
These are small biomarker studies, with platform dependence and likely overfitting. This is not practice guidance.
References
- Cuppen BVJ, et al. Baseline serum microRNAs and TNF-inhibitor response in rheumatoid arthritis. Arthritis Res Ther. 2016;18:189. DOI: 10.1186/s13075-016-1085-z
- Sode J, et al. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone. J Rheumatol. 2018;45:53-61. DOI: 10.3899/jrheum.170266
- Mucientes AM, et al. Plasma miR-134-5p: a candidate biomarker for predicting non-response to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2026. DOI: 10.3389/fimmu.2026.1783026
- Kirschner MB, Kao SC, Edelman JJ, et al. Hemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011;6(9):e24145. DOI: 10.1371/journal.pone.0024145